Mark Kris, MD: Choosing a Treatment in NSCLC
In your practice, what option do you choose?
Well, with a cancer that we’re told is not a squamous cell carcinoma, the first drug that we would recommend would be pemetrexed. It’s a very effective and safe drug. The second drug that would be recommended would be bevacizumab, so bevacizumab in combination with other chemotherapies has been shown to improve rates of response, duration of response, and survival. And, unless this patient has contraindications, and they do not, they would be candidates for bevacizumab. The third drug is somewhat more problematic.
mNSCLC: Case 1
RP is a 72 year old whose past medical history is notable for hypertension (well-controlled), hyperuricemia, and gout. He presents to his PCP with fatigue, progressive dyspnea, and a persistent, nonproductive cough of approximately 1 month’s duration. He is a former smoker and quit approximately 30 years ago.
Chest X-ray in October 2015 showed a large mass in the upper left lobe and CT scan showed a left pleural effusion and enlargement of the left mediastinal and hilar lymph node.
MRI of the brain was negative for intracranial metastases.
The patient underwent resection of the primary mass which showed large cell carcinoma. Pleural fluid was tapped and also positive.
His lung cancer was staged as 4. His biopsy was sent for molecular testing and showed no actionable mutations in EGFR or ALK.
His current performance status is 1.
